Business Description
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Business History
Price Overview
Last updated: Jun 27, 2026 10:09am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -1.90
Total Equity: $577.31M
Shares: 1,672,056,160
Total Debt: $378.99M
Cash: $797.80M
EBITDA: $11.38M
Total Debt: $378.99M
Cash: $797.80M
Revenue: $812.03M
Shares: 1,672,056,160
Revenue: $812.03M
Revenue: $812.03M
Revenue: $812.03M
Total Equity: $577.31M
Tax Rate: -690.1%
Equity: $577.31M
Total Debt: $378.99M
Cash: $797.80M
Current Liabilities: $127.15M
Long-Term Debt: $378.82M
Total Debt: $378.99M
Total Equity: $577.31M
Shares: 1,672,056,160
Shares: 1,672,056,160
CapEx: -$16.26M
Shares: 1,672,056,160
Stock Price: $18.50
Net Income: -$537.96M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 24, 2026 9:56am (3d ago)| Metric | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $294.0M | $258.5M | $306.1M | $412.3M | $812.0M |
| Cost of Revenue | $109.9M | $178.5M | $216.8M | $233.5M | $272.9M |
| Gross Profit | $184.2M | $80.0M | $89.3M | $178.8M | $539.2M |
| Operating Expenses | $45.1M | $395.8M | $408.9M | $435.9M | $494.1M |
| Operating Income | $139.1M | -$315.8M | -$319.6M | -$257.1M | $45.1M |
| Net Income | $27.7M | -$320.8M | -$341.4M | -$281.9M | -$538.0M |
| EBITDA | $254.5M | -$245.9M | -$260.8M | -$183.0M | $11.4M |
| EPS | $1.55 | $-1.57 | $-1.82 | $-2.70 | $-1.90 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 9:56am (3d ago)| Metric | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $53.5M | $107.2M | $56.4M | $64.0M | $797.8M |
| Total Current Assets | $214.7M | $516.0M | $242.6M | $215.7M | $997.8M |
| Total Assets | $2.6B | $717.4M | $412.9M | $343.7M | $1.1B |
| Current Liabilities | $320.3M | $136.9M | $95.1M | $165.4M | $127.1M |
| Long-Term Debt | $1.6B | $169.6M | $166.1M | $319.2M | $378.8M |
| Total Liabilities | $1.9B | $2.4B | $2.6B | $2.8B | $548.4M |
| Total Equity | $702.2M | -$1.7B | -$2.1B | -$2.5B | $577.3M |
| Retained Earnings | $503.3M | -$1.7B | -$2.1B | -$2.5B | -$2.5B |
Cash Flow (Annual)
Last updated: Jun 24, 2026 9:56am (3d ago)| Metric | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $277.0M | -$285.7M | -$276.1M | -$245.2M | $83.2M |
| Capital Expenditure | -$219.5M | -$42.3M | -$22.3M | -$8.4M | -$16.3M |
| Free Cash Flow | $57.6M | -$328.0M | -$298.4M | -$253.6M | $66.9M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$7.9M | $0 | $0 | $0 | $-113,000 |
| Net Change in Cash | -$6.7M | -$558.2M | -$51.1M | $8.0M | $732.0M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 7:18am (2h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$1.2B $1.2B – $1.2B
|
$1.4B $1.4B – $1.4B
|
$1.6B $1.6B – $1.7B
|
$1.8B $1.8B – $1.9B
|
| EBITDA |
-$329.3M -$340.8M – -$315.0M
|
-$382.8M -$383.3M – -$382.3M
|
-$444.6M -$454.8M – -$424.2M
|
-$502.5M -$514.0M – -$479.4M
|
| Net Income |
$565.9M $302.9M – $828.9M
|
$1.1B $644.2M – $1.5B
|
$1.3B $1.2B – $1.4B
|
$1.8B $1.6B – $1.8B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 9:56am (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -12.1% | +18.4% | +34.7% | +97.0% |
| Gross Profit Growth | -56.5% | +11.6% | +100.2% | +201.6% |
| Operating Income Growth | -327.0% | -1.2% | +19.5% | +117.5% |
| Net Income Growth | -1,256.8% | -6.4% | +17.4% | -90.8% |
| EBITDA Growth | -196.6% | -6.1% | +29.9% | +106.2% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 7:18am (2h ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-29 | POSTE GEORGE | A-Award | 1,600.00 | $15.62 | $24,992 |
| 2026-05-29 | Knowles Jonathan Kenneth Charles | A-Award | 1,600.00 | $15.62 | $24,992 |
| 2026-05-15 | Denton John Russel | F-InKind | 6,047.00 | $15.25 | $92,217 |
| 2026-05-15 | Power Luke Thomas | F-InKind | 9,771.00 | $15.25 | $149,008 |
| 2026-05-15 | Spetzler David Baxley | F-InKind | 13,856.00 | $15.25 | $211,304 |
| 2026-05-15 | Brille Brian J | F-InKind | 13,987.00 | $15.25 | $213,302 |
| 2026-05-15 | HALBERT DAVID D | F-InKind | 40,712.00 | $15.25 | $620,858 |
| 2026-05-11 | Vacirca Jeff L | P-Purchase | 31,050.00 | $16.15 | $501,426 |
| 2026-03-06 | Power Luke Thomas | A-Award | 63,971.00 | $0.00 | $0 |
| 2026-03-06 | Denton John Russel | A-Award | 63,971.00 | $0.00 | $0 |
| 2026-03-06 | Spetzler David Baxley | A-Award | 83,162.00 | $0.00 | $0 |
| 2026-03-06 | Brille Brian J | A-Award | 83,162.00 | $0.00 | $0 |
| 2026-03-06 | HALBERT DAVID D | A-Award | 320,112.00 | $0.00 | $0 |
| 2026-02-26 | Minor Lloyd | A-Award | 2,492.00 | $20.06 | $49,990 |
| 2026-02-26 | Vacirca Jeff L | A-Award | 2,492.00 | $20.06 | $49,990 |
| 2026-02-26 | Fredrickson David Paul | A-Award | 2,492.00 | $20.06 | $49,990 |
| 2026-02-26 | HALBERT JON | A-Award | 2,492.00 | $20.06 | $49,990 |
| 2026-02-26 | PHILLIPS T DANNY | A-Award | 3,739.00 | $20.06 | $75,004 |
| 2026-02-26 | CASTLEMAN PETER M | A-Award | 5,509.00 | $20.06 | $110,511 |
| 2026-01-09 | CASTLEMAN PETER M | M-Exempt | 2,500.00 | $18.60 | $46,500 |
Narrative Economics
market-narrative step).